Revision as of 08:24, 20 July 2019 edit Doctor.sebas (talk \| contribs) 18 edits No edit summary ← Previous edit		Revision as of 08:41, 20 July 2019 edit undo Doctor.sebas (talk \| contribs) 18 edits No edit summary Next edit →
Line 104: ==Heart Transplant== Circulating antibodies after [[heart transplantation]] (HTx) place patients at risk for [[cardiac allograft vasculopathy]] (CAV) and decreased survival. Circulating antibodies cause injury by activating the [[complement cascade]], the first step of which is binding of the antibody to C1q. The ability of an antibody to bind C1q is therefore a potential marker of [[cytotoxicity]]. Complement-binding C1q [[donor-specific antibodies]] (DSA) are associated with the subsequent development of non-fatal major adverse cardiac events (NF-MACE: [[myocardial infarction]], [[heart failure]], coronary intervention, defibrillator/pacemaker, [[strok]]e). <ref>Victor Arruarana, et all (2019). “The Impact of Complement-Binding Antibodies on Adverse Events Long-Term after Heart Transplantation”. Journal of Investigative Medicine. 67(1), 167-168. Doi:http://dx.doi.org/10.1136/jim-2018-000939.162</ref> ==References== {{Reflist}}

Complement component 1q: Difference between revisions